Leukemia, Mast-Cell

A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of >20% MAST CELLS, multi-organ failure and a short survival.

Drugs by status

Approved for this indication (1)

midostaurin

Phase 2 trials (18)

busulfan
cixutumumab
tacrolimus
paclitaxel
ibrutinib
plx9486
sunitinib
allogeneic hematopoietic stem cells
cyclosporine
mycophenolate
cyclophosphamide
allogeneic lymphocytes
alemtuzumab
methotrexate
fludarabine
thiotepa
autologous hematopoietic stem cells
gtb-3550

Phase 1 trials (2)

msk-2206
avapritinib

Other trials (6)

brentuximab vedotin
deferasirox
foscarnet
ganciclovir
valganciclovir
interferon alpha-2b

Organizations

Organization Involved with Phase 2 Indications (7)

Blueprint Medicines Corporation
National Cancer Institute (NCI)
University of Washington
Stanford University
University of Minnesota
University of Texas at Houston
The Leukemia and Lymphoma Society

Organization Involved with Phase 1 Indications (1)

AIDS Malignancy Consortium

Organization Involved with Other Experimental Indications (2)

National Heart, Lung, and Blood Institute (NHLBI)
Wake Forest University

ICD-10 crosswalk

C94.30 — Mast cell leukemia not having achieved remission